Lv11
90 积分 2024-08-09 加入
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
3小时前
待确认
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide
19天前
已完结
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study
1个月前
已完结
皖公网安备34019202002308
